Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 194,369,424
  • Shares Outstanding, K 6,065,650
  • Annual Sales, $ 48,851 M
  • Annual Income, $ 6,960 M
  • 36-Month Beta 0.91
  • Price/Sales 3.61
  • Price/Book 3.02

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.53 +0.76%
on 01/19/17
33.70 -5.73%
on 01/06/17
-1.08 (-3.29%)
since 12/20/16
3-Month
29.83 +6.50%
on 11/03/16
33.83 -6.09%
on 11/10/16
-0.77 (-2.37%)
since 10/20/16
52-Week
28.25 +12.46%
on 02/08/16
37.39 -15.03%
on 08/01/16
+1.11 (+3.62%)
since 01/20/16

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin

The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin

Top Analyst Reports for Gilead Sciences, Las Vegas Sands & Illinois Tool Works

Top Analyst Reports for Gilead Sciences, Las Vegas Sands & Illinois Tool Works

Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval

Teva Pharmaceutical Industries Ltd. (TEVA) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment....

Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout

Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.

Blog Coverage Eli Lilly Announced Acquisition of CoLucid; Adds Lasmiditan to the Pain Management Portfolio

LONDON, UK / ACCESSWIRE / January 19, 2017 / Active Wall St. blog coverage looks at the headline from Eli Lilly and Co. (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) as both companies announced...

Milner Therapeutics Institute Announces New Partnership with US Pharmaceutical Company Pfizer

Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune and Otsuka in the Milner Therapeutics Consortium

How to improve your sex life without breaking the bank

TRENTON, N.J. (AP) — For many older couples, fun in the bedroom requires help from prescription drugs, but prices of popular brand-name sexual dysfunction drugs have tripled since 2010 and insurance...

Investors: Free Options Reports for Apple, Mattel Inc, Morgan Stanley, Pfizer Inc. and Reynolds American Incorporated

InvestorsObserver issues critical PriceWatch Alerts for AAPL, MAT, MS, PFE, and RAI.

What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?

Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.

Technical Reports on Drug Makers Stocks -- Pfizer, Merck, AbbVie, and Johnson & Johnson

Today, Stock-Callers.com takes another look at the Drug Manufacturers space to see how current market conditions are influencing the performances of some major players in the industry. Under evaluation...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Support & Resistance

2nd Resistance Point 32.31
1st Resistance Point 32.04
Last Price 31.77
1st Support Level 31.58
2nd Support Level 31.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.